Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Overexpression × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡